Paper Status Tracking

Journals by Title

Journals by Subject

Contact us

	customer@davidpublishing.com
	3275638434

	Paper Publishing WeChat

Useful Links

Creative Commons Attribution-NonCommercial 4.0 International License

Article

Open Access

Safety, Efficacy and Cost Analysis of Rivaroxaban versus Fondaparinux for Thromboprophylaxis after Joint Replacement at an Inpatient Rehabilitation Facility

Author(s)

Nitika Agarwal, Noel Rao, Mary Mekheil, Nadia Tancredi and Jeffrey Oken

Full-Text PDF Download XML 5145 Views

DOI:10.17265/2328-2150/2015.11.006

Affiliation(s)

ABSTRACT

This study compares safety, efficacy, and cost of the new oral Factor Xa inhibitor rivaroxaban to fondaparinux, an injectable anticoagulant, for prevention of VTE (venous thromboembolism) after hip or knee arthroplasty within an IRF (inpatient rehabilitation facility). In this retrospective review, data was collected on the patients that were either status post total knee arthroplasty or total hip arthroplasty, admitted to the IRF over a 24 month period. All patients identified for inclusion in the study received either fondaparinux subcutaneously or rivaroxaban orally once daily as for VTE prevention. Primary efficacy outcomes were composite of any deep venous thrombosis, non-fatal PE (pulmonary embolism); and all-cause mortality. Primary safety outcomes were any major or non-major bleeding events. Analysis of 314 patient records (199 patients on rivaroxaban and 115 patients on fondaparinux) indicated no PE events. No DVT occurred in the patients prescribed rivaroxaban compared to 0.9% in the fondaparinux group. Major bleeding events occurred in 0.5% of patients prescribed rivaroxaban compared to 1.74% in fondaparinux group. Minor bleeding events occurred in 1% of patients prescribed rivaroxaban compared to 1.74% of patients in fondaparinux group. Direct acquisition cost analysis revealed 52% lower costs than fondaparinux, in the patients treated with rivaroxaban. In this study, rivaroxaban provided a safe and effective alternative to fondaparinux for prevention of VTE in post-operative total hip or knee replacement patients in the IRF setting. Rivaroxaban was also found to be favorable with respect to cost of acquisition, and ease of drug administration.

KEYWORDS

Rivaroxaban, fondaparinux, thromboprophylaxis, rehabilitation, arthroscopy, venous thromboembolism, cost analysis.

Cite this paper

Agarwal, N., et al. 2015. “Safety, Efficacy and Cost Analysis of Rivaroxaban versus Fondaparinux for Thromboprophylaxis after Joint Replacement at an Inpatient Rehabilitation Facility.” Journal of Pharmacy and Pharmacology 3 (11): 538-543.

References